Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Argenx's study flop in Sjögren's overshadows a win in celiac disease

Argenx on Thursday reported one success and one setback in its autoimmune disease pipeline, sending its shares tumbling. The Belgian-Dutch pharma said it is shuttering a Phase 3 trial of its ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 8 October →